didanosine	Didanosine	3	3	false	none	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  		D016049	D016049
didanosine	Didanosine	3	4	false	none	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		D016049	D016049
didanosine	Didanosine	3	5	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		D016049	D016049
didanosine	Didanosine	4	3	false	none	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		D016049	D016049
didanosine	Didanosine	4	4	false	none	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		D016049	D016049
didanosine	Didanosine	4	5	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		D016049	D016049
didanosine	Didanosine	4	6	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		D016049	D016049
didanosine	Didanosine	5	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		D016049	D016049
didanosine	Didanosine	5	4	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		D016049	D016049
didanosine	Didanosine	5	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		D016049	D016049
didanosine	Didanosine	5	6	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		D016049	D016049
didanosine	Didanosine	5	7	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		D016049	D016049
didanosine	Didanosine	6	4	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		D016049	D016049
didanosine	Didanosine	6	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		D016049	D016049
didanosine	Didanosine	6	6	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		D016049	D016049
didanosine	Didanosine	6	7	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		D016049	D016049
didanosine	Didanosine	6	8	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		D016049	D016049
didanosine	Didanosine	7	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		D016049	D016049
didanosine	Didanosine	7	6	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		D016049	D016049
didanosine	Didanosine	7	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		D016049	D016049
didanosine	Didanosine	7	8	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		D016049	D016049
didanosine	Didanosine	8	6	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		D016049	D016049
didanosine	Didanosine	8	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		D016049	D016049
didanosine	Didanosine	8	8	false	none	7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		D016049	D016049
didanosine	tenofovir disoproxil fumarate	3	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	3	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	3	5	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	3	5	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	4	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	4	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	4	5	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	4	5	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	5	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	5	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	5	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	5	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	5	7	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	5	7	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	6	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	6	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	6	7	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	6	7	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	7	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	7	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	7	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	7	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	8	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		3364	300195	D016049	C418563
didanosine	tenofovir disoproxil fumarate	8	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	3	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	3	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	3	5	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	3	5	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	4	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	4	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	4	5	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	4	5	true	positive	Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	5	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	5	3	true	positive	Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].  Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy.  Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	5	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	5	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	5	7	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	5	7	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	6	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	6	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	6	7	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	6	7	false	none	Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	7	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	7	5	true	positive	Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response.  Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)].  Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	7	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	7	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	8	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		3364	300195	D016049	C418563
Didanosine	tenofovir disoproxil fumarate	8	7	false	none	Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily.  7.2 Predicted Drug Interactions    Predicted drug interactions with didanosine delayed-release are listed in Table 6.  		3364	300195	D016049	C418563
